{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:39:29Z","timestamp":1791218369524,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Private Foundation of the Geneva University Hospitals","award":["75N9301900065"],"award-info":[{"award-number":["75N9301900065"]}]},{"name":"Giorgi-Cavaglieri foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients treated with anti-CD20 therapy are particularly at risk of developing severe coronavirus disease 2019 (COVID-19); however, little is known regarding COVID-19 vaccine effectiveness in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational cohort study assesses humoral and T-cell responses after vaccination with 2 doses of mRNA-based COVID-19 vaccines in patients treated with rituximab for rheumatic diseases or ocrelizumab for multiple sclerosis (n\u2005=\u200537), compared to immunocompetent individuals (n\u2005=\u200522).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies were detectable in only 69.4% of patients and at levels that were significantly lower compared to controls who all seroconverted. In contrast to antibodies, Spike (S)-specific CD4\u2005T cells were equally detected in immunocompetent and anti-CD20 treated patients (85\u201390%) and mostly of a Th1 phenotype. Response rates of S-specific CD8\u2005T cells were higher in ocrelizumab (96.2%) and rituximab-treated patients (81.8%) as compared to controls (66.7%). S-specific CD4\u2005and CD8\u2005T cells were polyfunctional but expressed more effector molecules in patients than in controls. During follow-up, 3 MS patients without SARS-CoV-2-specific antibody response had a mild breakthrough infection. One of them had no detectable S-specific T cells after vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study suggests that patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA COVID-19 vaccines, despite impaired humoral responses. This could play an important role in the reduction of complications of severe COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciab954","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T15:15:16Z","timestamp":1636989316000},"page":"e1037-e1045","source":"Crossref","is-referenced-by-count":107,"title":["Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study"],"prefix":"10.1093","volume":"75","author":[{"given":"Natacha","family":"Madelon","sequence":"first","affiliation":[{"name":"Center for Vaccinology, Department of Pathology and Immunology, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Geneva University Hospitals and University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Breville","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Division of Neurology, Geneva University Hospitals and University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ir\u00e8ne","family":"Sabater Royo","sequence":"additional","affiliation":[{"name":"Center for Vaccinology, Department of Pathology and Immunology, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Center for Vaccinology, Department of Pathology and Immunology, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego O","family":"Andrey","sequence":"additional","affiliation":[{"name":"Department of Diagnostics, Division of Laboratory Medicine; Geneva University Hospitals and University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California , San Diego, La Jolla, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California , San Diego, La Jolla, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Geneva Centre for Emerging Viral Diseases, Division of Infectious Diseases, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals and University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire Anne","family":"Siegrist","sequence":"additional","affiliation":[{"name":"Center for Vaccinology, Department of Pathology and Immunology, University of Geneva , Geneva , Switzerland"},{"name":"Center for Vaccinology, Geneva University Hospitals and Department of Woman, Child and Adolescent Medicine, Division of General Pediatrics, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Geneva University Hospitals and University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice H","family":"Lalive","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Division of Neurology, Department of Pathology and Immunology, Geneva University Hospitals and University of Geneva , Geneva , Switzerland and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud M","family":"Didierlaurent","sequence":"additional","affiliation":[{"name":"Center for Vaccinology, Department of Pathology and Immunology, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane S","family":"Eberhardt","sequence":"additional","affiliation":[{"name":"Center for Vaccinology, Department of Pathology and Immunology, University of Geneva , Geneva , Switzerland"},{"name":"Center for Vaccinology, Geneva University Hospitals and Department of Woman, Child and Adolescent Medicine, Division of General Pediatrics, University of Geneva , Geneva , Switzerland"},{"name":"Emory Vaccine Center, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"2022082503053525000_CIT0001","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022082503053525000_CIT0002","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann Neurol"},{"key":"2022082503053525000_CIT0003","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2022082503053525000_CIT0004","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"2022082503053525000_CIT0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022082503053525000_CIT0006","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cei.12390","article-title":"Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients","volume":"178","author":"Westra","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2022082503053525000_CIT0007","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur J Neurol"},{"key":"2022082503053525000_CIT0008","doi-asserted-by":"crossref","first-page":"e150175","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J Clin Invest"},{"key":"2022082503053525000_CIT0009","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"2022082503053525000_CIT0010","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022082503053525000_CIT0011","first-page":"17562864211012835","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2022082503053525000_CIT0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"2022082503053525000_CIT0013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3201\/eid2701.203611","article-title":"Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France","volume":"27","author":"Gallais","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2022082503053525000_CIT0014","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"2022082503053525000_CIT0015","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"2022082503053525000_CIT0016","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/jcm10081605","article-title":"Head-to-head evaluation of five automated SARS-CoV-2 serology immunoassays in various prevalence settings","volume":"10","author":"Andrey","year":"2021","journal-title":"J Clin Med"},{"key":"2022082503053525000_CIT0017","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2022082503053525000_CIT0018","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2022082503053525000_CIT0019","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"2022082503053525000_CIT0020","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"2022082503053525000_CIT0021","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022082503053525000_CIT0022","doi-asserted-by":"crossref","first-page":"e149150","DOI":"10.1172\/JCI149150","article-title":"First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19","volume":"131","author":"Mazzoni","year":"2021","journal-title":"J Clin Invest"},{"key":"2022082503053525000_CIT0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cells8010012","article-title":"Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients","volume":"8","author":"Gingele","year":"2018","journal-title":"Cells"},{"key":"2022082503053525000_CIT0024","doi-asserted-by":"crossref","first-page":"25690","DOI":"10.1073\/pnas.2012249117","article-title":"B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis","volume":"117","author":"Nissimov","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022082503053525000_CIT0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022082503053525000_CIT0026","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"2022082503053525000_CIT0027","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1742-2094-8-146","article-title":"Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders","volume":"8","author":"Lehmann-Horn","year":"2011","journal-title":"J Neuroinflammation"},{"key":"2022082503053525000_CIT0028","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"2022082503053525000_CIT0029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"2022082503053525000_CIT0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503053525000_CIT0031","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022082503053525000_CIT0032","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab954\/42416692\/ciab954.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e1037\/45514350\/ciab954.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e1037\/45514350\/ciab954.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T23:09:07Z","timestamp":1661382547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/1\/e1037\/6430423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,17]]},"published-print":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab954","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.21.21260928","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,11,17]]}}}